RPC Expands Sterilant Portfolio with Peracidin Acquisition

CEO Vern Taaffe described the deal as a strategic milestone that strengthens the company's position in dialysis technology while opening doors to broader healthcare and water treatment sectors. By absorbing the Peracidin brand, RPC aims to maintain supply stability and service for existing clients who rely on these high-quality peroxyacetic acid solutions.

This expansion aligns with RPC’s ongoing efforts to advance industry standards, particularly through its active membership in the Association for the Advancement of Medical Instrumentation. Headquartered in Tucson with production facilities in Minnesota, the company intends to leverage its technical expertise to uphold the legacy of the acquired product line while ensuring uninterrupted service for its global distribution partners.